3P Biopharmaceuticals has completed the project for the expansion and improvement of its facilities in Noáin (Spain) that had been carried out over the past months. The investment exceeded the 5 million euros invested in this project in addition to the 8 million euros that 3P has invested since 2013.
The new facilities have already been GMP-certified by the AEMPS (The Spanish Agency of Medicines and Medical Devices).
3P Biopharmaceuticals is a CDMO specialized in the process development and GMP production of biologics. The company collaborates with its clients to provide personalized solutions at every stage of process development and GMP manufacturing from pre-clinical to commercial supply.
3P has also acquired a Single-Use Multi-Parallel Bioreactor: ambr 250 that together with other analytic equipment, have required an investment of almost 1 million euros. The ambr 250 allows 3P to develop 24 different experiments concurrently.
The expansion of the GMP manufacturing area has focused on the amplification of the bacterial area. Thus, allowing 3P to transfer in and manufacture such products at different stages of their clinical development.
The mammalian cell culture area has been enhanced thanks to the acquisition of a new 50 L single use bioreactor. This provides an attractive option for small scale batch manufacture as well as for intermediate cell expansion.
The analytical area has been also equipped with state-of-the-art technologies like mass spectrometry, chromatography equipment, bioanalytical analysers and a Maurice system (Protein Simple). All these technologies allow the rapid determination of identity, purity and characterization of proteins with a higher precision.
This Project specific to facility growth and adaptation, has been accompanied with an important increase in human resource. During 2018, more than 50 professionals have joined the company and is expected to exceed the 245 personnel forecasts for 2019.
“This investment is consolidating the important successes we have achieved with our clients, with two of their products already in commercial stages,” Damaso Molero, General Manager at 3P says. “We have no doubts that our capacity and knowledge in mammalian cell culture will allow us to compete in this important market”.